Cargando…
Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
Little is known about Subgenomic RNA (sgRNA) dynamics in patients with Coronavirus diseases 2019 (COVID-19). We collected 147 throat swabs, 74 gut swabs and 46 plasma samples from 117 COVID-19 patients recruited in the LOTUS China trial (ChiCTR2000029308) and compared E and orf7a sgRNA load in patie...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wuhan Institute of Virology, Chinese Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762994/ https://www.ncbi.nlm.nih.gov/pubmed/35234623 http://dx.doi.org/10.1016/j.virs.2022.01.008 |
_version_ | 1784633863695237120 |
---|---|
author | Zou, Xiaohui Mu, Shengrui Wang, Yeming Guo, Li Ren, Lili Deng, Xiaoyan Li, Haibo Zhao, Jiankang Zhang, Yulin Li, Hui Lu, Binghuai Huang, Chaolin Cao, Bin |
author_facet | Zou, Xiaohui Mu, Shengrui Wang, Yeming Guo, Li Ren, Lili Deng, Xiaoyan Li, Haibo Zhao, Jiankang Zhang, Yulin Li, Hui Lu, Binghuai Huang, Chaolin Cao, Bin |
author_sort | Zou, Xiaohui |
collection | PubMed |
description | Little is known about Subgenomic RNA (sgRNA) dynamics in patients with Coronavirus diseases 2019 (COVID-19). We collected 147 throat swabs, 74 gut swabs and 46 plasma samples from 117 COVID-19 patients recruited in the LOTUS China trial (ChiCTR2000029308) and compared E and orf7a sgRNA load in patients with different illness duration, outcome, and comorbidities. Both sgRNAs were detected in all the three types of samples, with longest duration of 25, 13, and 17 days for E sgRNA, and 32, 28, and 17 days for orf7a sgRNA in throat, gut, and plasma, respectively. A total of 95% (57/60) of patients had no E sgRNA detected after 10 days post treatment, though 86% of them were still E RNA positive. High correlation on titer was observed between sgRNA encoding E and orf7a gene. sgRNA showed similar variation in the standard care and Lopinavir-Ritonavir group. Patients with diabetes and heart diseases showed higher pharyngeal E sgRNA at the first day (P = 0.016 and 0.013, respectively) but no difference at five days after treatment, compared with patients without such commodities. Patients with hypertension and cerebrovascular diseases showed no difference in the pharyngeal sgRNA levels at both one and five days after treatment, compared with patients without these two commodities. E sgRNA levels in the initial infection showed no correlation with the serum antibody against spike, nucleoprotein, and receptor binding domains at ten days later. sgRNA lasted a long period in COVID-19 patients and might have little effect on humoral response. |
format | Online Article Text |
id | pubmed-8762994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wuhan Institute of Virology, Chinese Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-87629942022-01-18 Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients Zou, Xiaohui Mu, Shengrui Wang, Yeming Guo, Li Ren, Lili Deng, Xiaoyan Li, Haibo Zhao, Jiankang Zhang, Yulin Li, Hui Lu, Binghuai Huang, Chaolin Cao, Bin Virol Sin Research Article Little is known about Subgenomic RNA (sgRNA) dynamics in patients with Coronavirus diseases 2019 (COVID-19). We collected 147 throat swabs, 74 gut swabs and 46 plasma samples from 117 COVID-19 patients recruited in the LOTUS China trial (ChiCTR2000029308) and compared E and orf7a sgRNA load in patients with different illness duration, outcome, and comorbidities. Both sgRNAs were detected in all the three types of samples, with longest duration of 25, 13, and 17 days for E sgRNA, and 32, 28, and 17 days for orf7a sgRNA in throat, gut, and plasma, respectively. A total of 95% (57/60) of patients had no E sgRNA detected after 10 days post treatment, though 86% of them were still E RNA positive. High correlation on titer was observed between sgRNA encoding E and orf7a gene. sgRNA showed similar variation in the standard care and Lopinavir-Ritonavir group. Patients with diabetes and heart diseases showed higher pharyngeal E sgRNA at the first day (P = 0.016 and 0.013, respectively) but no difference at five days after treatment, compared with patients without such commodities. Patients with hypertension and cerebrovascular diseases showed no difference in the pharyngeal sgRNA levels at both one and five days after treatment, compared with patients without these two commodities. E sgRNA levels in the initial infection showed no correlation with the serum antibody against spike, nucleoprotein, and receptor binding domains at ten days later. sgRNA lasted a long period in COVID-19 patients and might have little effect on humoral response. Wuhan Institute of Virology, Chinese Academy of Sciences 2022-01-17 /pmc/articles/PMC8762994/ /pubmed/35234623 http://dx.doi.org/10.1016/j.virs.2022.01.008 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Zou, Xiaohui Mu, Shengrui Wang, Yeming Guo, Li Ren, Lili Deng, Xiaoyan Li, Haibo Zhao, Jiankang Zhang, Yulin Li, Hui Lu, Binghuai Huang, Chaolin Cao, Bin Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients |
title | Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients |
title_full | Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients |
title_fullStr | Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients |
title_full_unstemmed | Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients |
title_short | Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients |
title_sort | characterization of two sars-cov-2 subgenomic rna dynamics in severe covid-19 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762994/ https://www.ncbi.nlm.nih.gov/pubmed/35234623 http://dx.doi.org/10.1016/j.virs.2022.01.008 |
work_keys_str_mv | AT zouxiaohui characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT mushengrui characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT wangyeming characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT guoli characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT renlili characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT dengxiaoyan characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT lihaibo characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT zhaojiankang characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT zhangyulin characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT lihui characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT lubinghuai characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT huangchaolin characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients AT caobin characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients |